Quanterix Corporation (QTRX) is a Billerica, Massachusetts-based life sciences company whose Simoa ultra-sensitive biomarker detection technology and Akoya-derived spatial biology platforms are used in Alzheimer's diagnostics, protein research and drug development. On November 18, the stock fell 27.97% to $2.06 as of late-morning trading, compared with the prior session's close of $2.86. The direction is decisively negative. The immediate reason is a surprise chief executive departure: Everett Cunningham resigned as president, CEO and board member effective immediately, and the company named Chief Commercial Officer Jim Gute as interim CEO while it searches for a permanent replacement.
Cunningham joined Quanterix as president and CEO in January 2026, arriving from Illumina with a mandate to rebuild commercial execution and revive growth after a difficult stretch that included the Akoya Biosciences acquisition, a goodwill impairment and a deep guidance reset. He leaves before completing a single full year, departing to take the top job at GeneDx by mid-December.
The disclosure, filed with regulators and announced before the opening bell, stated that the resignation was not related to any disagreement over operations, policies, practices, financial disclosures, accounting or legal matters. Cunningham will remain available through December 11 to support an orderly transition. The board has engaged an executive search firm and will consider both internal and external candidates.
For a company of Quanterix's size — roughly $100 million in market value after today's decline — the loss of a chief executive mid-turnaround is a governance overhang rather than an operational event. Gute only became chief commercial officer in August 2026, so the internal bench behind him is thin, and the market must now underwrite a strategy whose principal author has departed. That uncertainty, not any change in the underlying business, is what repriced the shares.
The damage was contained by the company's decision to reaffirm the financial outlook it issued on November 9 alongside third-quarter results. Quanterix continues to expect 2026 revenue of $142 million to $146 million, non-GAAP gross margin of 48% to 50%, and a year-end cash balance of approximately $70 million with no debt.
Those numbers already reflected a sober reality. Third-quarter revenue was $35 million, up 6.3% sequentially but down 13.1% year over year, while the GAAP net loss was $21.6 million. Cash usage of $16.2 million in the quarter left $80.7 million on the balance sheet, implying roughly six quarters of runway at the current burn. Management still targets cash-flow breakeven in 2027, a goal it has already pushed back once. Reaffirmation removes a worst-case scenario — that the CEO saw something the market did not — but it does not restore confidence in the timeline.
This was a company-specific repricing, not a sector event. Large-cap life science tools names traded modestly higher through the morning, and major indices were firm. Quanterix instead opened at $2.43, well below the prior close, and slid through the session to an intraday low near $2.06, a decline far steeper than any peer move.
Participation was heavy. More than 1.1 million shares changed hands by late morning against a typical full-day turnover of roughly 350,000, and the selling was persistent across consecutive hours rather than a single opening print. Technically, the drop takes the shares below the 52-week low of $2.15 set earlier in the year and leaves the stock roughly 76% below its 52-week high of $8.77. The gap-down open also broke the $2.70 to $3.00 range that had contained trading since late October.
The scale runs from 0, meaning no meaningful news and a normal price move, to 100, meaning transformative news and an extreme, rare move. Quanterix earns 66 out of 100.
The verified news is materially significant for a company this small: an immediate CEO resignation less than a year into the role, with the executive departing for a peer in the diagnostics space, creates genuine leadership and execution uncertainty. It is a governance shock rather than a fundamental one, since guidance was reaffirmed. The price response was unusual: today's 27.97% decline is roughly 6.4 times the stock's average absolute daily move of about 4.4% over the past 60 sessions, and no session in that stretch produced a move of comparable magnitude. Moderate-to-strong news plus a rare, high-volume decline combine into the final score.
The near-term focus is the search for a permanent chief executive and whether the board appoints an internal candidate or looks outside. Fourth-quarter results, expected in early March 2027, will be the first real test of whether Gute can deliver the roughly $40 million in quarterly revenue implied by the full-year outlook — a bar management itself has described as achievable but not assured.
Commercially, investors will track LucentAD Complete test volumes, the pace of new clinical reference laboratory partnerships, and reimbursement expansion beyond Florida's Medicaid program. On the regulatory side, the timing of the 510(k) submission for the HD-X as an in vitro diagnostic, now targeted for 2027, remains a key milestone. Risks include continued instrument placement weakness, academic and pharma budget softness, a lengthening path to cash-flow breakeven, and the possibility that leadership turnover disrupts the commercial reorganization underway.
Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies rather than a full catalogue. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions earn a place in this featured section. Bots vary widely by strategy, timeframe, performance metrics and the symbols they trade, so the lineup rotates as market conditions shift. Reviewing the trending list is a practical way to see which approaches are working right now, and a useful starting point for building a watchlist around live performance data.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
QTRX moved below its 50-day moving average on November 11, 2026 date and that indicates a change from an upward trend to a downward trend. In 39 of 41 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on QTRX as a result. In 75 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for QTRX turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In 41 of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
The 10-day moving average for QTRX crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QTRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
QTRX broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +22.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where QTRX advanced for three days, in 209 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 128 of 144 cases where QTRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 89%.
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.577) is normal, around the industry mean (4.142). P/E Ratio (-1.105) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.894) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. QTRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QTRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of protein diagnostic platform
Industry MedicalNursingServices